Terms: = Ovarian cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Prognosis
12 results:
1. Neuroendocrine neoplasms of the ovary: an analysis of clinicopathological characteristics and prognosis with a focus on histological grading.
Huang W; Bao Y; Luo X; Yao L; Yuan L
Endocrine; 2022 Jun; 77(1):188-198. PubMed ID: 35538309
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Approach to Neuroendocrine Neoplasm Associated With ovarian Teratoma.
Opalińska M; Sowa-Staszczak A; Olearska H; Ulatowska-Bialas M; Gilis-Januszewska A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2021; 12():770266. PubMed ID: 34917031
[TBL] [Abstract] [Full Text] [Related]
3. [Digestive Surgery Intervention for Gynecological Malignant Tumor].
Kameyama H; Shimada Y; Abe K; Oyanagi H; Nakano M; Nakano M; Ichikawa H; Hanyu T; Takizawa K; Nagahashi M; Sakata J; Kobayashi T; Nishikawa N; Enomoto T; Wakai T
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2176-2178. PubMed ID: 32156870
[TBL] [Abstract] [Full Text] [Related]
4. Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma.
Horn LC; Höhn AK; Krücken I; Stiller M; Obeck U; Brambs CE
J Cancer Res Clin Oncol; 2020 Apr; 146(4):971-983. PubMed ID: 31927619
[TBL] [Abstract] [Full Text] [Related]
5. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.
Bi R; Bai Q; Zhu X; Tu X; Cai X; Jiang W; Xu X; Tang S; Ge H; Chang B; Cheng Y; Gan H; Zhou X; Yang W
Diagn Pathol; 2019 Aug; 14(1):96. PubMed ID: 31455365
[TBL] [Abstract] [Full Text] [Related]
6. Contribution of lymph node staging method and prognostic factors in malignant ovarian sex cord-stromal tumors: A world wide database analysis.
Wang J; Li J; Chen R; Lu X
Eur J Surg Oncol; 2018 Jul; 44(7):1054-1061. PubMed ID: 29705285
[TBL] [Abstract] [Full Text] [Related]
7. Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer.
Lian S; Zhai X; Wang X; Zhu H; Zhang S; Wang W; Wang Z; Huang J
Medicine (Baltimore); 2016 Jul; 95(30):e4328. PubMed ID: 27472713
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression.
Guo Q; Cheng Y; Liang T; He Y; Ren C; Sun L; Zhang G
Sci Rep; 2015 Dec; 5():17683. PubMed ID: 26631459
[TBL] [Abstract] [Full Text] [Related]
9. Thyroid transcription factor-1 (ttf-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus.
Ervine A; Leung S; Gilks CB; McCluggage WG
Histopathology; 2014 May; 64(6):840-6. PubMed ID: 24267480
[TBL] [Abstract] [Full Text] [Related]
10. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases.
Tabrizi AD; Kalloger SE; Köbel M; Cipollone J; Roskelley CD; Mehl E; Gilks CB
Int J Gynecol Pathol; 2010 Mar; 29(2):99-107. PubMed ID: 20173494
[TBL] [Abstract] [Full Text] [Related]
11. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract] [Full Text] [Related]
12. An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis.
Di Leo A; Bajetta E; Biganzoli L; Bohm S; Mariani L; Mènard S; Pilotti S; Fabbiani M; Gebbia V; Oriana S
Eur J Cancer; 1995 Dec; 31A(13-14):2248-54. PubMed ID: 8652251
[TBL] [Abstract] [Full Text] [Related]
